IP Library Granted Patent US 12681022
Granted Patent B2
US 12681022 · App. 17/611,874 · Granted Jul 14, 2026

Method for selecting a patient for a reperfusion therapy

Inventor: Joan Montaner Villalonga (Barcelona, ES)
Assignee: FUNDACIÓ HOSPITAL UNIVERSITARI VALL D'HEBRON—INSTITUT DE RECERCA
G01N33/6893G01N2333/58G01N2800/2871G01N2800/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12681022
App. No.
17/611,874
Granted
Jul 14, 2026
Kind
B2
Abstract

The invention relates to a method for selecting a patient suffering stroke for a reperfusion therapy based on determining the level of retinol binding protein-4 (RBP4) and N-terminal fragment of B-type natriuretic peptide (NT-proBNP) in an isolated sample of said patient. The invention also relates to a method of differentiating ischemic stroke from haemorrhagic stroke and to kits comprising reagents to carry out the methods.

Claims (14)

1 . A method for diagnosing and treating large vessel occlusion (LVO) in a patient, said method comprising:

(a) determining the levels of RBP4 and of NT-proBNP in an isolated sample of a subject;

(b) comparing the levels of RBP4, and of NT-proBNP with a corresponding reference value, wherein said reference value or interval is selected from a value or interval of values from a reference subject suffering from LVO,

(c) diagnosing the patient with LVO when at least the levels of RBP4 and NT-proBNP are both within the value or interval of values from the reference subject suffering from LVO; and

(d) administering a reperfusion therapy comprising mechanical thrombectomy to the diagnosed patient.

2 . The method according to claim 1 , further comprising determining the level of glial fibrillary acid protein (GFAP) in the isolated sample.

3 . The method according to claim 1 , further comprising measuring one or more clinical parameters selected from blood pressure, glycemia, levels of blood d-dimer, age, scores from systematic assessment tools of stroke-related neurologic deficits, gender, and combinations thereof.

4 . The method according to claim 1 , wherein the reperfusion therapy comprises first administering an antithrombotic agent to the patient followed by mechanical thrombectomy.

5 . The method according to claim 1 , comprising determining the levels of RBP4, NT-proBNP, GFAP, and, d-dimer.

6 . A method for diagnosing and treating large vessel occlusion (LVO) in a subject, the method comprising:

(a) determining the levels of GFAP and d-dimer in an isolated sample of a subject and determining blood pressure of the subject;

(b) comparing the levels of GFAP, d-dimer, and blood pressure with a corresponding reference value, wherein said reference value or interval is selected from a value or interval of values from a reference subject suffering from LVO,

(c) diagnosing the subject with LVO when at least the levels of GFAP, d-dimer, and blood pressure are within the value or interval of values from the reference subject suffering from LVO; and

(d) administering a reperfusion therapy comprising mechanical thrombectomy to the diagnosed subject.